A phase IV study of zoledronic acid therapy in patients with bone metastases from breast cancer or hormone resistant prostate cancer, or bone involvement from multiple myeloma, assessing long-term efficacy and safety.

Trial Profile

A phase IV study of zoledronic acid therapy in patients with bone metastases from breast cancer or hormone resistant prostate cancer, or bone involvement from multiple myeloma, assessing long-term efficacy and safety.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Bone metastases; Breast cancer; Multiple myeloma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 21 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Planned number of patients changed from 200 to 73 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top